KOL Insights - Non-Small Cell Lung Cancer - Targeted Therapies

Explore the comprehensive landscape of targeted therapies in non-small cell lung cancer (NSCLC) with this detailed report, which analyzes insights from 12 key opinion leaders across the US and Europe. This report delves into the current and future treatment pathways, focusing on the role of established and novel therapies such as Tagrisso, Rybrevant, and Enhertu. Gain a deeper understanding of the challenges and opportunities presented by new formulations, the impact of recent drug approvals, and the evolving treatment algorithms. By examining expert perspectives on tyrosine kinase inhibitors, KRAS inhibitors, and other targeted agents, the report provides valuable insights into the future directions of NSCLC treatment.

Key Questions Answered:

• How is AstraZeneca's Tagrisso currently used, and how might its use evolve with ongoing trials?
• What are the current and future uses of Genmab/Johnson & Johnson's Rybrevant?
• What impact will the subcutaneous formulation of Rybrevant have on its clinical use?
• What are the expectations for novel EGFR and HER tyrosine kinase inhibitors?
• How is Enhertu utilized in clinical practice for NSCLC?
• What are the views on recent approvals like Datroway, Emrelis, and Ensacove?
• How do experts use ALK inhibitors, and which are preferred?
• What is the potential of pipeline KRAS inhibitors in NSCLC treatment?
• How do specialists expect the MET, RET, ROS1, and BRAF inhibitors to change treatment algorithms?
• How is the targeted treatment landscape for NSCLC expected to evolve in the near-to-medium term?

Key Brands:

Partial List of Participating Experts:

• Assistant Professor of Medicine and Medical Oncologist, Duke University, US
• Jeffrey A. Brown and Barbara Horovitz Brown Associate, Professor of Translational Medicine, Director of Thoracic Oncology at the Lifespan Cancer Institute, in Providence, RI, US
• Director of the Thoracic Cancer Clinical Research Program and Associate Professor of Oncology at Johns Hopkins Medicine, MD, US
• Consultant Clinical Oncologist, Queen Elizabeth Hospital Birmingham, UK
• Professor and head of department, Aix Marseille University, Assistance Publique-Hopitaux de Marseille, Marseille, France
• Head of the Thoracic Cancer Group in the Department of Medicine at Gustave Roussy, Villejuif, France

Methodology:

Therapy Trend reports are developed through in-depth interviews with the world's foremost Key Opinion Leaders (KOLs) on the current and future treatment landscapes in major disease areas. KOLs are carefully selected based on strict screening criteria, including their global reputation, clinical expertise, and influence within their therapeutic area. Each interview is guided by a meticulously crafted discussion guide. These guides are developed in collaboration with KOLs and peer-reviewed by industry experts to ensure that the questions are comprehensive and pertinent to current market dynamics. Through continuous market monitoring over a 12-month period following the publication of each report, we provide timely updates from KOLs on key news events, market shifts, and clinical developments.

What makes our reports different?

FirstWord Reports, a trusted industry leader with an exclusive focus on the pharmaceutical sector, delivers in-depth, actionable insights for biopharma professionals and decision-makers. Our deep industry knowledge enables us to provide relevant and valuable insights that help you identify emerging trends and navigate complex challenges effectively. Backed by extensive research and independent, impartial insights from leading experts and KOLs, our reports deliver the accuracy and reliability you need. With exclusive access to interviews and data unavailable elsewhere, along with ongoing market monitoring, we give you a comprehensive view of market dynamics. Covering over 40 dynamic disease areas and providing physician intelligence, including KOL insights and quantitative physician surveys, as well as industry expert views on issues in medical affairs, digital health, sales & marketing, market access, and other areas, our reports empower you to make smarter, data-driven decisions and maintain a competitive edge in a fast-moving industry.